Person:
GÜNER, ALTUĞ

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

GÜNER

First Name

ALTUĞ

Name

Filters

20222
Reset filters

Settings

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Publication
    Pituitary involvement as a primary manifestation of granulomatosis with polyangiitis
    (Wolters Kluwer Medknow Publications, 2022-05-01) Koç, Emine R.; KOÇ, EMİNE RABİA; Güllü, Gizem; GÜLLÜ, GİZEM; Güner, Altuğ; GÜNER, ALTUĞ; Tolunay, Şahsine; TOLUNAY, ŞAHSİNE; Özpar, Rifat; ÖZPAR, RİFAT; Dalkılıç, Hüseyin E.; DALKILIÇ, HÜSEYİN EDİZ; Tıp Fakültesi; Nöroloji Ana Bilim Dalı; 0000-0002-0264-7284; 0000-0001-6649-9287; A-7083-2015
    Granulomatosis with polyangiitis is a systemic necrotizing granulomatous vasculitis that can predominantly affect systemic small- and medium-sized vessels. Isolated pituitary gland involvement at the onset of the disease is extremely rare in granulomatosis with polyangiitis and usually associated with other organ involvement, especially upper and lower respiratory tract and kidneys. This report highlights granulomatosis with polyangiitis -related pituitary dysfunction with clinical, radiological, and laboratory findings.
  • Thumbnail Image
    Publication
    How do COVID-19 vaccines affect rheumatic diseases?
    (Turkish League Against Rheumatism, 2022-09-20) Altan, Lale; Mısırcı, Salim; Yağcı, İlker; Karacaatlı, Meltem; Özkan, Feyza Ünlu; Güner, Altuğ; Aktaş, İlknur; ALTAN İNCEOĞLU, LALE; MISIRCI, SALİM; GÜNER, ALTUĞ; Tıp Fakültesi; Fiziksel Tıp ve Rehabilitasyon Ana Bilim Dalı; AAH-1652-2021; DHX-0337-2022; EXG-9080-2022
    Objectives: This study aims to investigate the effects of novel coronavirus disease 2019 (COVID-19) vaccines administered in Turkiye on disease activity and the side effects in the patients with inflammatory rheumatic disease (IRD).Patients and methods: Between September 2021 and February 2022, a total of 536 patients with IRD (225 males, 311 females; mean age: 50.5 +/- 12.6 years; range, 18 to 93 years) who were vaccinated against COVID-19 and followed in the outpatient setting were included in the study. Vaccination status of the patients and whether they had COVID-19 were questioned. All patients were asked to rate their anxiety about the vaccination on a scale of 0-10 before and after the shots. They were asked whether they experienced any side effects and an increase in IRD complaints after vaccination.Results: A total of 128 (23.9%) patients were diagnosed with COVID-19 before the first vaccination. Totally, 180 (33.6%) patients were vaccinated with CoronaVac (Sinovac) and 214 (39.9%) patients with BNT162b2 (Pfizer-BioNTech). Also, 142 (26.5%) patients were given both vaccines. When the anxiety level of the patients before the first vaccination was questioned, 53.4% reported that they had no anxiety. The rate of patients without any anxiety after vaccination was 67.9%. Comparison of pre- (median Q3=6) and post-vaccine (median Q3=1) anxiety values showed a statistically significant difference (p<0.001). A total of 283 (52.8%) patients reported side effects after vaccination. When both vaccines were compared with each other, the rate of the side effects was higher in the BNT162b2 group (p<0.001) and also in the CoronaVac plus BNT162b2 group (p=0.022). There was no statistically significant difference between BNT162b2 and CoronaVac plus BNT162b2 in terms of side effects (p= 0.066). Forty-five (8.4%) patients had increased rheumatic complaints after vaccination.Conclusion: The lack of a significant increase in disease activity after COVID-19 vaccination in patients with IRD and the absence of serious side effects requiring hospitalization support the safety of vaccines in this patient group.